Vir downsizes by 12%, will close St. Louis and Portland sites in 2024 to save $40M+ annually
As Vir Biotechnology expands beyond infectious diseases, where it made a mark in Ebola and the early days of Covid, the biotech will downsize and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
